Geron (NASDAQ:GERN) Stock Price Down 4%

Geron Co. (NASDAQ:GERN) shares were down 4% during mid-day trading on Tuesday . The stock traded as low as $3.54 and last traded at $3.58. Approximately 3,076,463 shares changed hands during trading, a decline of 72% from the average daily volume of 11,094,822 shares. The stock had previously closed at $3.73.

Analyst Ratings Changes

Several equities analysts have issued reports on GERN shares. The Goldman Sachs Group upped their target price on shares of Geron from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Wedbush restated an “outperform” rating and set a $6.00 target price on shares of Geron in a research note on Wednesday, April 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $5.00 target price on shares of Geron in a research note on Thursday, April 11th.

Geron Stock Down 0.6 %

The company’s 50 day moving average price is $2.83 and its two-hundred day moving average price is $2.28. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.14. The stock has a market cap of $1.95 billion, a P/E ratio of -10.79 and a beta of 0.62.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Geron had a negative net margin of 77,691.14% and a negative return on equity of 63.33%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. During the same quarter in the prior year, the business earned ($0.10) EPS. The business’s quarterly revenue was down 77.7% on a year-over-year basis. Equities analysts forecast that Geron Co. will post -0.34 earnings per share for the current year.

Institutional Investors Weigh In On Geron

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vishria Bird Financial Group LLC increased its holdings in Geron by 17.7% in the 1st quarter. Vishria Bird Financial Group LLC now owns 24,265 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 3,650 shares in the last quarter. Moody National Bank Trust Division grew its holdings in Geron by 4.0% during the 4th quarter. Moody National Bank Trust Division now owns 132,053 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 5,079 shares in the last quarter. Amalgamated Bank grew its holdings in Geron by 9.0% during the 3rd quarter. Amalgamated Bank now owns 69,122 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 5,681 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in Geron by 4.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 130,096 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 5,880 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Geron by 101.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 6,757 shares in the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.